SCNX NASDAQ
Scienture Holdings, Inc.
1W: -45.0%
1M: -58.7%
3M: -55.8%
YTD: -70.7%
1Y: -82.5%
$0.16
-0.02 (-10.33%)
Weekly Expected Move ±16.4%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
2 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (22)
Scienture announces 1-for-25 reverse stock split
Scienture announces 1-for-25 reverse stock split
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Monday's Intraday Session
Scienture Holdings, Inc. GAAP EPS of -$2.70, revenue of $0.43M
EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market
12 Health Care Stocks Moving In Thursday's After-Market Session
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
Scienture Holdings, Inc. (NASDAQ:SCNX) Sees Significant Growth in Short Interest
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
Why Is Scienture Stock Gaining Today?
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
Scienture Holdings, Inc. (SCNX) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025